Skip to main content
Fig. 1 | BMC Rheumatology

Fig. 1

From: Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Fig. 1

Physician-reported reasons given for patient switching from 1st to 2nd line TNFi. * Secondary lack of efficacy: loss of response over time; † I wanted to use bDMARD that can be used as a monotherapy; ‡ I wanted to use a bDMARD that can be used in combination. MOA: Mode of action; bDMARD: biologic Disease Modifying Anti Rheumatic Drug

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us